Returning in September as a digital event, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD, dry AMD, DME, IRDs and more.
Discover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics, Biogen, Gyroscope Therapeutics, Novartis, Horama and REGENXBIO.
Join 150+ fellow industry attendees from discovery, preclinical and clinical backgrounds, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders.
This meeting will allow you to:
Hear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome inflammation
Highlight optogenetics and gene agnostic approaches from SparingVision, GenSight Biologics and Bionic Sight
Learn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures
Discuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO
Gain key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing
Explore the realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics
Hear pharma representatives discuss the opportunities and realities of collaborating with biotechs, with experience from Novartis
Hear from a Luxturna patient to understand their first-hand experience of receiving the therapy, and have an opportunity to ask them your questions
Highlight progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR
Visit the website to access your free event guide!
Time: 8:00 am - 5:00 pm
Conference + Workshop Day (Pay by May 28): USD 2346.00,
Conference + Workshop Day (Pay by June 25): USD 2596.00,
Conference + Workshop Day (Pay by July 30): USD 2796.00,
Conference + Workshop Day (Pay by August 27): USD 3046.00,
Conference + Workshop Day (Standard Rate): USD 3296.00,
Conference Only (Pay by May 28): USD 1599.00,
Conference Only (Pay by June 25): USD 1699.00,
Conference Only (Pay by July 30): USD 1899.00,
Conference Only (Pay by August 27): USD 1999.00,
Conference Only (Standard Rate): USD 2099.00
Speakers: Nicolas Ferry, Chief Development Officer, HORAMA, Peter Campochiaro, Director, Retinal Cell and Molecular Laboratory; Professor of Ophthalmology, Johns Hopkins University School of Medicine, Rei Nakamura, Clinical Country Lead, Biogen, Sanford Boye, Director of Vector Core, Powell Gene Therapy Center, University of Florida and Chief Technology Officer, Atsena Therapeutics, Shannon Boye, Founder and Chief Scientific Officer, Atsena Therapeutics, Abraham Scaria, Chief Scientific Offier, IVERIC Bio, Aniz Girach, Chief Medical Officer, ProQR, Claire Gelfman, Chief Scientific Officer, Foundation Fighting Blindness, Daniel Chung, Chief Medical Officer, SparingVision, Dominik Fischer, Principal Investigator and Consultant Ophthalmic Surgeon, Oxford Eye Hospital, Eric Kelsic, Chief Executive Officer, Dyno Therapeutics, Francine Behar-Cohen, Founder and Chief Innovation Officer, Eyevensys, Gaelle Lefevre, Head of Project Management, HORAMA, Gil Carrasquinho, Vice President and Head of Cell Therapy, Santen, Glenn Yiu, Associate Professor, University of California, Davis, Jacque Duncan, Professor, Clinical Ophthalmology, University of California San Fransisco, Jake Ternent, Patient, Luxterna, Jose-Alain Sahel, Chairman and Professor, Ophthalmology, University of Pittsburgh, Magali Taiel, Chief Medical Officer, GenSight Biologics, Nadia Waheed, Associate Professor in Ophthalmology Tufts University Medical School Chief Medical Officer, Gyroscope Therapeutics, Sheila Nirenberg, Professor and Founder, Bionic Sight, Stavros Ntogiako, Head of Luxturna and Gene Therapy, Novartis, Stephen Poor, Director of External Opportunities and Translational Biomarkers, Novartis, Steve Pakola, Chief Medical Officer, REGENXBIO, Stylianos Michalakis, Co-founder and Chief Scientific Advisor, ViGeneron, Sue Washer, Chief Executive Officer, AGTC, Thomas Ciulla, Vitreoretinal Medicine and Surgery, Chief Medical Officer and Chief Development Officer, Clearside Biomedical Inc., Virginia Haurigot, Head of Ocular Research, Spark Therapeutics, Ying Kai Chan, Visiting Scholar, Harvard University, Udo Maier, Head of Research Beyond Borders Europe, Boehringer Ingelheim